Older Eli Lilly's drug fails Alzheimer's prevention trial

📆 3/9/2023 5:50 AM
📰 Reuters

⏱ Reading Time:
17 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 97%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

An early-generation Alzheimer's drug from Eli Lilly and Co failed to slow cognitive decline in patients treated before they showed symptoms, but the large trial found a strong link between levels of brain plaques and disease progression, the company said on Wednesday.

Although Lilly halted development of solanezumab, it supported, along with the National Institute on Aging and others, the randomized clinical trial of the drug in over 1,100 asymptomatic Alzheimer's patients.

"Even at this preclinical stage of Alzheimer's disease, we are going to have to be more aggressive with amyloid." said Dr. Reisa Sperling, a neurologist at Harvard-affiliated Brigham and Women’s Hospital, who led the study. "We need to get people's amyloid lower, very fast, and keep it there."

Write Comment

Sadly, not surprising, given the mechanism.

Keep trying

I’m guessing they have no ex-executives on the FDA board of directives!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly’s Insulin Decision Puts Others in Hot SeatHeard on the Street: Eli Lilly’s decision to drastically cut the list price of some of its insulin products moves the spotlight to drug-industry middlemen Because everyone will increase their price to make a profit . They are also going to cut production. Dark Brandon turning up the heat! Another Biden win for the people!
Source: WSJ - 🏆 98. / 63 Read more »